MeSH tree: C10.574.950.050
UC Irvine researchers conducted a study to better understand the molecular basis of amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder in which patients lose the ability to move, becoming weak and wheelchair ...
Jun 4, 2025
0
57
As the global population ages, the risk of developing neurodegenerative diseases such as dementia, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) continues to rise. But the molecular mechanisms ...
Jun 2, 2025
0
40
Scientists from St. Jude Children's Research Hospital and Washington University in St. Louis report mechanistic insights into the role of biomolecular condensation in the development of neurodegenerative disease.
May 28, 2025
0
18
Dr. Simrit Parmar, an associate professor in the College of Medicine at Texas A&M University and founder of the clinical-stage biotech company Cellenkos Inc. in Houston, has invented a new cell therapy that shows strong promise ...
May 23, 2025
0
66
For patients with amyotrophic lateral sclerosis (ALS), rapid eye movement (REM) inhibition via receipt of antidepressant medication is associated with a trend toward survival benefit, according to a study presented at the ...
May 22, 2025
0
15
During REM sleep, the body enters a state of paralysis. This can pose a danger for patients with weakened diaphragms due to neuromuscular diseases. Now new research published at the ATS 2025 International Conference has shown ...
May 21, 2025
0
17
Using the gene scissors CRISPR and stem cells, researchers at Stockholm University and the UK Dementia Research Institute (UK DRI) at King's College London have managed to identify a common denominator for different gene ...
May 20, 2025
0
36
If you've been on Instagram recently, you may have seen Insta stories of giddy teens dumping water—which doesn't even contain ice—on their friends in the name of #SpeakYourMIND. Influencers give pretty speeches in which they ...
May 15, 2025
0
16
The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard treatment for amyotrophic lateral sclerosis slowed functional decline and extended the lifespan of people ...
May 13, 2025
0
72
Unlike other pathologies, amyotrophic lateral sclerosis (ALS) cannot be reproduced accurately in animal models, complicating the development of effective drugs. Faced with this challenge, a group of researchers from IMDEA ...
May 13, 2025
0
26
